AU2013295047B2 - HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders - Google Patents

HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders Download PDF

Info

Publication number
AU2013295047B2
AU2013295047B2 AU2013295047A AU2013295047A AU2013295047B2 AU 2013295047 B2 AU2013295047 B2 AU 2013295047B2 AU 2013295047 A AU2013295047 A AU 2013295047A AU 2013295047 A AU2013295047 A AU 2013295047A AU 2013295047 B2 AU2013295047 B2 AU 2013295047B2
Authority
AU
Australia
Prior art keywords
ala
gly
asp
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013295047A
Other languages
English (en)
Other versions
AU2013295047A1 (en
Inventor
Philippe Bridonneau
Anne Goubier
Yolande Misseri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calliditas Therapeutics France SAS
Original Assignee
Genkyotex France SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genkyotex France SA filed Critical Genkyotex France SA
Publication of AU2013295047A1 publication Critical patent/AU2013295047A1/en
Application granted granted Critical
Publication of AU2013295047B2 publication Critical patent/AU2013295047B2/en
Assigned to GENKYOTEX reassignment GENKYOTEX Alteration of Name(s) of Applicant(s) under S113 Assignors: GENTICEL
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013295047A 2012-07-23 2013-07-23 HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders Ceased AU2013295047B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305898.4 2012-07-23
EP12305898.4A EP2689786A1 (en) 2012-07-23 2012-07-23 HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
PCT/EP2013/065549 WO2014016312A1 (en) 2012-07-23 2013-07-23 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders

Publications (2)

Publication Number Publication Date
AU2013295047A1 AU2013295047A1 (en) 2015-02-05
AU2013295047B2 true AU2013295047B2 (en) 2018-02-22

Family

ID=48832935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013295047A Ceased AU2013295047B2 (en) 2012-07-23 2013-07-23 HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders

Country Status (21)

Country Link
US (1) US9827302B2 (enExample)
EP (2) EP2689786A1 (enExample)
JP (1) JP6466328B2 (enExample)
KR (1) KR20150031487A (enExample)
CN (1) CN104736173B (enExample)
AU (1) AU2013295047B2 (enExample)
CA (1) CA2879999A1 (enExample)
DK (1) DK2874657T3 (enExample)
ES (1) ES2712647T3 (enExample)
HR (1) HRP20190108T1 (enExample)
HU (1) HUE042808T2 (enExample)
LT (1) LT2874657T (enExample)
MX (1) MX2015001021A (enExample)
PL (1) PL2874657T3 (enExample)
PT (1) PT2874657T (enExample)
RS (1) RS58313B1 (enExample)
RU (1) RU2015100212A (enExample)
SI (1) SI2874657T1 (enExample)
SM (1) SMT201900057T1 (enExample)
TR (1) TR201900695T4 (enExample)
WO (1) WO2014016312A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
EP3323424A1 (en) * 2016-11-17 2018-05-23 Cyanimal IP Cyaa polypeptides as immune enhancer
CA3109889A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072266A1 (en) * 2004-03-18 2007-03-29 Xavier-Edmond-Edouard Preville Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209817A (ja) 1988-02-17 1989-08-23 Yamaha Corp 浮動少数点形ディジタル・アナログ変換器
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
US8183007B2 (en) 2008-07-22 2012-05-22 Promega Corporation ADP detection based methods using adenylate cyclase and bioluminescence
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072266A1 (en) * 2004-03-18 2007-03-29 Xavier-Edmond-Edouard Preville Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Clifford et al., British Journal of Cancer, 2003, 88:63-73. *
GenBank Accession No. CAA68613 (January 5, 1988) *
GMIRA S ET AL, RESEARCH IN MICROBIOLOGY, ELSEVIER, AMSTERDAM, NL, (20011201), vol. 152, no. 10, doi:10.1016/S0923-2508(01)01272-4, ISSN 0923-2508, pages 889 - 900 *
JANA HOLUBOVA ET AL, INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MACROBIOLOGY, USA, vol. 80, no. 3, doi:10.1128/IAI.05711-11, ISSN 0019-9567, (20120301), pages 1181 - 1192 *
Munagala et al., International Journal of Oncology, 2009,34:263-271. *
PREVILLE XAVIER ET AL, CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050115), vol. 65, no. 2, ISSN 0008-5472, pages 641 - 649 *
REINIS M, "Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, (20040401), vol. 6, no. 2, ISSN 1464-8431, pages 206 - 211 *

Also Published As

Publication number Publication date
EP2874657B1 (en) 2018-10-17
RU2015100212A (ru) 2016-09-10
CA2879999A1 (en) 2014-01-30
JP2015524420A (ja) 2015-08-24
EP2689786A1 (en) 2014-01-29
JP6466328B2 (ja) 2019-02-13
CN104736173B (zh) 2019-02-05
EP2874657A1 (en) 2015-05-27
PL2874657T3 (pl) 2019-05-31
PT2874657T (pt) 2019-02-18
ES2712647T3 (es) 2019-05-14
DK2874657T3 (en) 2019-02-11
TR201900695T4 (en) 2019-03-21
US9827302B2 (en) 2017-11-28
KR20150031487A (ko) 2015-03-24
SI2874657T1 (sl) 2019-03-29
RS58313B1 (sr) 2019-03-29
LT2874657T (lt) 2019-02-25
HUE042808T2 (hu) 2019-07-29
HK1208822A1 (en) 2016-03-18
CN104736173A (zh) 2015-06-24
SMT201900057T1 (it) 2019-02-28
US20150250867A1 (en) 2015-09-10
MX2015001021A (es) 2015-08-05
HRP20190108T1 (hr) 2019-03-22
WO2014016312A1 (en) 2014-01-30
AU2013295047A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
KR102148413B1 (ko) 이종 폴리펩티드를 포함하는 ＣｙａＡ에 기초한 키메라 단백질 및 면역 반응의 유도에 있어서의 그의 용도
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
CZ298347B6 (cs) Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
EP3481854A1 (en) Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof
JP2010532656A (ja) 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質
DK2874657T3 (en) HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE FOR INPUT OF IMMUNE RESPONSES TO HPV INFECTION AND HPV-INDUCED DISORDERS
US8309096B2 (en) Fusion protein
RU2590701C2 (ru) Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
KR101713635B1 (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도
AU2008206463B2 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
HK1208048B (en) Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
HK1208822B (en) Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: GENKYOTEX

Free format text: FORMER NAME(S): GENTICEL

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired